Você procurou por: osteoporosbehandling (Sueco - Inglês)

osteoporosbehandling krävs vanligtvis under en lång tidsperiod.
osteoporosis-therapy is usually required for a long period.

preotact förfylld penna har utvecklats för att underlätta för dig att ta din osteoporosbehandling.
the preotact pre-filled pen has been designed especially to make it easy for you to take your osteoporosis treatment.

tabell 1 visar de biverkningar som inträffat i de två kliniska prövningarna avseende osteoporosbehandling i större incidens än placebo.
table 1 lists adverse reactions occurring in the two osteoporosis treatment clinical trials that occurred at an incidence greater than placebo.

riskreduktionen var 51 % hos bisfosfonatnaiva patienter och 42 % hos patienter som tilläts undergå samtidig osteoporosbehandling.
the risk reduction was 51% in bisphosphonate-naïve patients and 42% in patients allowed to take concomitant osteoporosis therapy.

hos växande råttor fanns inga tecken på en försämrad benmineralisering även i doser högre än 5 000 gånger de doser som krävs för osteoporosbehandling.
in growing rats, there was no evidence of impaired mineralization even at doses greater than 5,000 times the dose required for osteoporosis treatment.

vitamin d - och kalciumtillägg i samband med specifik osteoporosbehandling till patienter med risk för vitamin d - och kalciumbrist.
vitamin d and calcium supplement as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin d and calcium deficiency.

tabell 1: biverkningar som observerats i placebokontrollerade kliniska prövningar avseende osteoporosbehandling hos fler kvinnor som behandlats med fablyn än hos kvinnor som fått placebo
table 1: adverse reactions observed in placebo-controlled osteoporosis treatment clinical trials in more fablyn-treated women than in placebo-treated women

samtidig annan osteoporosbehandling inkluderade: kalcitonin, raloxifen, tamoxifen, hormonsubstitutionsbehandling, tibolon, men exkluderade andra bisfosfonater.
concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates.

i en öppen studie behandlades 503 postmenopausala kvinnor med svår osteoporos som haft en fragilitetsfraktur under de senaste 3 åren (83 % hade tidigare fått osteoporosbehandling) med forsteo i upp till 24 månader.
in an open-label study, 503 postmenopausal women with severe osteoporosis and a fragility fracture within the previous 3 years (83 % had received previous osteoporosis therapy) were treated with forsteo for up to 24 months.

under observationsperioden tilläts andra osteoporosbehandlingar och ytterligare bedömningar av kotfrakturer gjordes.
during this observational period, other osteoporosis treatments were allowed and additional assessment of vertebral fractures was performed.